<?xml version="1.0" encoding="UTF-8"?>
<p>Antimicrobial resistance (AMR) is one of the most important challenges in modern clinical practice [
 <xref rid="r1" ref-type="bibr">1</xref>,
 <xref rid="r2" ref-type="bibr">2</xref>]. It is a multifactorial problem that must be tackled from different angles [
 <xref rid="r3" ref-type="bibr">3</xref>]. One of these angles pertains to the domain of medicine regulation. The European Medicines Agency (EMA) together with European Union (EU) countries and the European Commission (EC) has a strategy for AMR that covers also the re-evaluation of the product information that is available to the European patients and healthcare professionals. This process occurs via specific regulatory measures called referral procedures [
 <xref rid="r4" ref-type="bibr">4</xref>].
</p>
